Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

(Reuters) - Amgen Inc, the world's largest biotechnology company, said U.S. health regulators approved its Prolia injection for a new use as a treatment to increase bone mass in men with osteoporosis ...

Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone.

LOS ANGELES - With the launch of the first prescription osteoporosis medication 15 years ago, millions of Americans with the bone-thinning disease began taking the drugs and never looked back. But now ...

Prolia (denosumab) is a prescription drug used to treat osteoporosis and strengthen bones in certain people. This drug can interact with some other medications. For example, Prolia can interact with ...

Purpose. Trends in the use of different treatments for osteoporosis among the civilian, ambulatory U.S. population are described. Methods. Data from the Medical Expenditure Panel Survey (MEPS) were ...

Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for ...

Stoboclo® and Osenvelt® (CT-P41) received Health Canada Notice of Compliance for all indications referencing Prolia® and Xgeva®, respectively1,2The approval is based on the totality of evidence ...